Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu | (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats:
- Alabama Drug Discovery Alliance
- Biochemistry and Molecular Genetics
- Biomatrix Engineering and Regenerative Medicine
- Cell biology
- Center for Biophysical Sciences and Engineering
- CCTS
- Center for Metabolic Bone Disease
- Microbiology
- Neurobiology
- Comprehensive Neuroscience Center
- Pathology, research shared with MS2
- Pharmacology and Toxicology
- Physiology and Biophysics
- UAB Research Foundation/IIE
- Research Administration
FASEB is the largest coalition of biological and biomedical research associations in the United States.
Single-nucleus RNA-sequencing in a newborn pig model showed increased cell cycle activity and proliferation in cardiomyocytes, which helped remuscularize the left ventricle after experimental heart attack.
X-ray crystallography revealed the structure of the HIV-1 matrix protein at 2.1 angstroms resolution, advancing understanding of key mechanisms of viral assembly.
Surprisingly, several competing models for this clathrin-mediated endocytosis all appear to function in two cell lines tested.
All of the newly diagnosed glioblastoma multiforme patients enrolled in a Phase 1 clinical trial have exceeded both their median and expected progression-free survivals. Two patients, to date, have exceeded their expected overall survival.
To facilitate gene-level queries of data from more than 10,000 cancer patient transcriptome sequences and proteomics data from 2,000 patients, researchers have developed a user-friendly cancer data analysis web platform called UALCAN.
The biodegradable nanovehicles accumulated in human breast cancer tumors in mice after systemic injection, and they inhibited oncogene expression and extended survival of the mice.
The $20 million National Science Foundation award will help UAB and eight other Alabama-based universities build research infrastructure. UAB’s share will be about $2 million.
The drug inhibits the kinase Cdk5, found in mature neurons. Cdk5 has long been implicated in neuropsychiatric and neurodegenerative conditions, but previous inhibitors have largely failed to reach the brain through the blood-brain barrier.
This discovery validates siderophore secretion as a drug target in tuberculosis and reveals a new mechanism for putative drugs. Many tuberculosis bacteria are highly resistant to multiple antibiotics.